ARK Genomic Revolution ETF (BATS:ARKG) Reaches New 1-Year High – Should You Buy?

ARK Genomic Revolution ETF (BATS:ARKG)’s stock price hit a new 52-week high on Monday . The company traded as high as $37.71 and last traded at $37.31, with a volume of 407026 shares traded. The stock had previously closed at $36.86.

ARK Genomic Revolution ETF Trading Down 1.6%

The business has a 50-day moving average price of $31.35 and a 200-day moving average price of $30.07.

Hedge Funds Weigh In On ARK Genomic Revolution ETF

Institutional investors have recently modified their holdings of the company. NewEdge Advisors LLC raised its stake in ARK Genomic Revolution ETF by 49.4% during the 1st quarter. NewEdge Advisors LLC now owns 5,384 shares of the company’s stock valued at $112,000 after purchasing an additional 1,780 shares during the last quarter. Creative Planning bought a new stake in shares of ARK Genomic Revolution ETF in the 2nd quarter valued at approximately $255,000. Baird Financial Group Inc. raised its stake in ARK Genomic Revolution ETF by 81.0% during the second quarter. Baird Financial Group Inc. now owns 71,977 shares of the company’s stock worth $1,753,000 after acquiring an additional 32,221 shares in the last quarter. Strategic Wealth Investment Group LLC bought a new position in ARK Genomic Revolution ETF during the 2nd quarter valued at about $38,000. Finally, Group One Trading LLC acquired a new position in shares of ARK Genomic Revolution ETF in the 2nd quarter worth approximately $2,274,000.

ARK Genomic Revolution ETF Company Profile

The ARK Genomic Revolution ETF (ARKG) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund is an actively managed fund that targets companies involved in the genomics industry. ARKG was launched on Oct 31, 2014 and is managed by ARK.